Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2000
11/28/2000US6153193 Compositions for targeting biological agents
11/28/2000US6153183 A modified human interleukin-3 polypeptide, comprises the replacement of 6 to about 44 residues at positions 17-118 of native interleukin-3 by other amino acids with the proviso that asparagine at position 101 and lysine at position 116
11/28/2000US6153129 Production scale method of forming microparticles
11/28/2000CA2200795C Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
11/28/2000CA2068943C 1,3-oxathiolanes useful in the treatment of hepatitis
11/28/2000CA2066428C Structural alterations of the egf receptor gene in human gliomas
11/23/2000WO2000070351A2 Protein-protein interactions and methods for identifying them
11/23/2000WO2000070341A2 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
11/23/2000WO2000070099A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000WO2000070092A1 Expression of ets-domain proteins in cancer
11/23/2000WO2000070051A1 NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
11/23/2000WO2000070049A2 Extracellular signaling molecules
11/23/2000WO2000070047A2 Full-length molecules expressed in human tissues
11/23/2000WO2000070045A1 Ox2 receptor homologs
11/23/2000WO2000070036A2 Genes expressed in hippocampus
11/23/2000WO2000070028A1 Sphingosine kinase enzyme
11/23/2000WO2000070025A1 Methods of using rnase p reaction mechanisms of action
11/23/2000WO2000070017A2 Methods using of fab i and compounds modulating fab i activity
11/23/2000WO2000069898A2 Molecular interactions in allergy cells
11/23/2000WO2000069897A2 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
11/23/2000WO2000069896A2 Molecular interactions in haematopoietic cells
11/23/2000WO2000069887A2 Rapid dehydration of proteins
11/23/2000WO2000069838A1 Ion channel modulating agents
11/23/2000WO2000069832A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000WO2000069826A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000WO2000069810A1 Glucagon antagonists/inverse agonists
11/23/2000WO2000069794A2 Use of calcium-activated potassium channel-modulating agents
11/23/2000WO2000069515A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
11/23/2000WO2000069510A1 Energized trace elements
11/23/2000WO2000069472A2 Enzyme-activated anti-tumor prodrug compounds
11/23/2000WO2000069471A1 Enhanced transdermal anesthesia of local anesthetic agents
11/23/2000WO2000069468A1 Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
11/23/2000WO2000069467A1 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
11/23/2000WO2000069463A1 Compositions and methods for treating cell proliferation disorders
11/23/2000WO2000069460A1 TREATMENT WITH ANTI-ErbB2 ANTIBODIES
11/23/2000WO2000069459A1 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
11/23/2000WO2000069451A1 A method of identifying therapeutic compounds for a treatment of hepatic disorders
11/23/2000WO2000069449A2 Conditioned cell culture medium compositions and methods of use
11/23/2000WO2000069446A1 Combination therapy for treating hypercholesterolemia
11/23/2000WO2000069445A1 Combination therapy for treating hypercholesterolemia
11/23/2000WO2000069439A1 Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
11/23/2000WO2000069438A1 Pharmaceutical combination of neurokinin receptor antagonist and proton pump inhibitor
11/23/2000WO2000069434A1 Dfmo and celecoxib in combination for cancer chemoprevention and therapy
11/23/2000WO2000069433A1 Antagonists of gonadotropin releasing hormone
11/23/2000WO2000069431A1 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
11/23/2000WO2000069427A1 Composition and method for treating limb ischemia
11/23/2000WO2000069424A2 Method of treating psychotic disorders
11/23/2000WO2000069413A1 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
11/23/2000WO2000069412A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
11/23/2000WO2000069408A1 Methods of regulating the condition of mammalian keratinous tissue
11/23/2000WO2000069390A2 Compositions for improving bioavailability of orally administered drugs
11/23/2000WO2000069277A1 A composition containing carvacrol and thymol for use as a bactericide
11/23/2000WO2000069269A1 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
11/23/2000WO2000069255A1 Anti-inflammatory therapy for inflammatory mediated infection
11/23/2000WO2000041540A3 Herbal supplement for increased muscle strength and endurance for athletes
11/23/2000WO2000040232A3 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
11/23/2000WO2000038706A3 Methods for treating cancer and for mediating chemotaxis of dendritic cells
11/23/2000WO2000037685A9 Method of identifying a psychotropic agent using differential gene expression
11/23/2000WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof
11/23/2000WO2000037067A9 Sensitizing agents for the treatment of skin lesions
11/23/2000WO2000036918A9 Methods and compositions for treatment of cell proliferative disorders
11/23/2000WO2000032267A3 Device for locally delivering a drug in a body cavity
11/23/2000WO2000032221A3 Promotion or inhibition of angiogenesis and cardiovascularization
11/23/2000WO2000030681A9 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
11/23/2000WO2000028020A3 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
11/23/2000WO2000027194A9 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
11/23/2000WO2000026348A3 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
11/23/2000WO2000023100A3 Genes and proteins predictive and therapeutic for renal disease and associated disorders
11/23/2000WO2000019978A3 Compositions and methods for enhancing receptor-mediated cellular internalization
11/23/2000WO2000017369A3 Alzheimer's disease secretase
11/23/2000WO2000015790A3 Leptin induced genes
11/23/2000WO2000015666A3 Compositions and methods for the treatment of tumors
11/23/2000WO1999061398A3 24-hydroxyvitamin d, analogs and uses thereof
11/23/2000WO1999004775A3 Method of treating dopaminergic and gaba-nergic disorders
11/23/2000DE19923427A1 Device for improved delivery of active agents to skin, useful e.g. for administering opiates, contains agent that increases local skin temperature or blood flow
11/23/2000DE19921794A1 Neue pharmazeutische Zusammensetzung New pharmaceutical composition
11/23/2000CA2374085A1 Tumour treatment with anti-erbb2 antibodies
11/23/2000CA2373938A1 Compositions and methods for treating cell proliferation disorders
11/23/2000CA2373935A1 A method of identifying therapeutic compounds for a treatment of hepatic disorders
11/23/2000CA2373931A1 Dfmo and celecoxib in combination for cancer chemoprevention and therapy
11/23/2000CA2373892A1 Glucagon antagonists/inverse agonists
11/23/2000CA2373855A1 Method of treating psychotic disorders
11/23/2000CA2373815A1 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
11/23/2000CA2373681A1 Pharmaceutical compositions for treating angina and/or anginal equivalents, and kit relating thereto
11/23/2000CA2373614A1 Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants
11/23/2000CA2373509A1 Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
11/23/2000CA2373486A1 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
11/23/2000CA2373231A1 Extracellular signaling molecules
11/23/2000CA2373194A1 Methods of regulating the condition of mammalian keratinous tissue
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372919A1 Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
11/23/2000CA2372794A1 Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
11/23/2000CA2372549A1 Ox2 receptor homologs
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372119A1 Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
11/23/2000CA2371212A1 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000CA2370245A1 Enzyme-activated anti-tumor prodrug compounds
11/23/2000CA2369376A1 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for prevention of cancer in at-risk subjects
11/23/2000CA2368833A1 Molecules expressed in hippocampus
11/23/2000CA2368640A1 A composition containing carvacrol and thymol for use as a bactericide
1 ... 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 ... 1151